Skip to main content
Fig. 3 | Cost Effectiveness and Resource Allocation

Fig. 3

From: Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong

Fig. 3

Tornado Diagram for the ICER of pembrolizumab vs. DTIC. (a) The vertical line in the middle indicates the ICER of the base-case scenario ($35,993). (b) The orange bar indicates the ICER result when the minimum value of the input is used, while the blue bar indicates the ICER result when that maximum value of the input is used

Back to article page